Insulin Resistance (Human)(33 expert discussions analyzed)

Insulin resistance is a condition in which cells throughout the body stop responding normally to insulin — the hormone that signals cells to absorb glucose from the bloodstream. The pancreas compensates by producing more insulin, creating a state of chronically elevated insulin (hyperinsulinemia) that precedes elevated blood glucose by years or even decades. This is why fasting insulin is a more sensitive early warning marker than fasting glucose: by the time glucose rises into the prediabetic range, significant metabolic damage may already have occurred. Andrew Koutnik, a metabolic researcher who manages his own Type 1 diabetes, frames this directly: 'Insulin moves before glucose. If you wait for the glucose flag, you've already missed years.'

The liver is the primary site where insulin resistance begins, according to Robert Lustig, a neuroendocrinologist at UCSF. His central mechanistic argument is that dietary fructose — particularly from added sugars in processed foods — is metabolized in the liver in a way that suppresses mitochondrial function, promotes fat accumulation in the liver, and drives systemic insulin resistance. A fructose metabolite called methylglyoxal permanently inactivates an enzyme called AMP kinase, which normally signals cells to burn energy. Fructose also drives production of uric acid, which blocks the transport of fatty acids into mitochondria for burning. Lustig's clinical claim — supported by his own research — is that removing added sugar from the diet can produce measurable improvement in metabolic syndrome markers within ten days. David Unwin, a UK general practitioner with a published primary-care cohort, reinforces this with clinical evidence: many common 'healthy' carbohydrates (rice, bananas, wholemeal bread) act as hidden sugars in people who are already insulin-resistant, and a structured low-carbohydrate intervention has achieved type 2 diabetes remission rates above 50% in his practice, consistent with the DiRECT trial. Tim Noakes pushes this framing furthest, treating dietary carbohydrate as largely unnecessary — a position that goes beyond what the trial evidence supports and that sits outside mainstream nutrition science.

Beyond diet, the evidence points to a multi-lever picture. Muscle is the body's largest glucose sink — when you contract muscle, it absorbs glucose independently of insulin. This is why resistance training and post-meal walking are among the most consistently supported non-dietary interventions for insulin sensitivity. Mike Mutzel, a metabolic health educator, argues that exercise may reduce visceral fat — the metabolically active fat around organs — more effectively than dietary change alone. Will Bulsiewicz, a gastroenterologist, adds a distinct mechanism: fiber deficiency (affecting roughly 95% of Americans) promotes gut dysbiosis, which allows bacterial endotoxins called lipopolysaccharides to leak into the bloodstream, triggering chronic inflammation that directly impairs insulin signaling. The short-chain fatty acids produced when gut bacteria ferment fiber also activate the same appetite-suppressing hormones (GLP-1 and PYY) targeted by drugs like semaglutide.

A minority position deserves separate treatment, because it inverts everything above. Peter Osborne argues that type 2 diabetes is substantially a nutrient deficiency disease: zinc and magnesium are required to manufacture insulin, chromium supports the insulin receptor, and deficiency in any of them may worsen glucose control. The underlying biology is real — these minerals genuinely are involved — and one of his specific points is independently well recognized: metformin depletes vitamin B12, and the resulting fatigue or nerve symptoms are easy to mistake for the diabetes itself. Where he departs from the rest of this evidence base is the claim that carbohydrate restriction misses the real issue. That contradicts the single strongest convergence in this topic. It is also relevant that he sells the nutrient testing and the supplements he recommends. The distinction that matters for a reader: these minerals are necessary for glucose metabolism, but being necessary in a pathway is not the same as being the limiting factor in a disease. Correcting a genuine deficiency can modestly shift numbers. There is no good evidence it changes the course of type 2 diabetes.

The cardiovascular implications of insulin resistance are significant and contested. Cardiologist Aseem Malhotra argues that standard LDL cholesterol is a weak independent predictor of heart disease risk, and that insulin resistance and chronic inflammation are the true upstream drivers of arterial damage. He and Lustig both point to the triglyceride-to-HDL ratio as a more actionable cardiovascular risk marker — it reflects how the liver is processing sugar and serves as a reliable proxy for insulin resistance. Lustig states that a triglyceride-to-HDL ratio above 2.5 signals a metabolic problem, while a ratio below 1.5 indicates good metabolic health. The metabolic framing adds something real: insulin resistance is an independent risk factor worth measuring, and communicating absolute rather than relative risk is a genuine improvement in how statin decisions get made. But the claim that LDL is not causal runs against a large body of evidence — genetic studies and trials across several different LDL-lowering therapies consistently show that lowering LDL reduces cardiovascular events. The useful part of this argument and the overreaching part are separable, and worth separating.

The downstream consequences of unaddressed insulin resistance extend beyond cardiovascular disease. Benjamin Bikman, a metabolic researcher at Brigham Young University, frames insulin resistance as the common metabolic root under type 2 diabetes, heart disease, polycystic ovary syndrome, and parts of Alzheimer's risk. Dale Bredesen, a neurologist at UCLA, argues that brain insulin resistance — sometimes called 'type 3 diabetes' in research literature — is a central driver of Alzheimer's pathology, and that multi-domain lifestyle intervention addressing metabolic health, sleep, inflammation, and vascular function can reduce cognitive decline risk. This prevention framing is supported by the FINGER trial, a mainstream-backed randomized controlled trial of multi-domain lifestyle intervention. Bredesen's stronger claim — that established Alzheimer's can be reversed — is contested in mainstream neurology.